Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.37 |
| ▸ | HTR3B | O95264 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.37 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | TPMT | P51580 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29960733 | 0.89 | IDO1 (0.35) | TSHRIDO1TDP1ALDH1A1KDM4E | |
| SCHEMBL78950 | 0.84 | TNKS2 (0.42) | TSHRIDO1ALDH1A1CA2DAO | |
| SCHEMBL11931401 | 0.84 | TDP1 (0.34) | IDO1TDP1ALDH1A1KDM4EALOX5 | |
| SCHEMBL13180741 | 0.84 | CNR1 (0.38) | IDO1TDP1ALDH1A1KDM4EALOX5 | |
| SCHEMBL1834422 | 0.84 | DAO (0.39) | TDP1ALDH1A1KDM4EALOX5GAA | |
| SCHEMBL1247139 | 0.84 | TDP1 (0.34) | IDO1TDP1ALDH1A1KDM4EALOX5 | |
| SCHEMBL2355446 | 0.82 | TSHR (0.57) | TSHRIDO1ALDH1A1DAOCNR1 | |
| SCHEMBL13150551 | 0.80 | GABRA1 (0.38) | TSHRIDO1TDP1ALDH1A1KDM4E | |
| SCHEMBL63871 | 0.78 | TDP1 (0.53) | TSHRTDP1ALDH1A1KDM4EALOX5 | |
| SCHEMBL7700731 | 0.77 | CHKA (0.50) | TSHRTDP1ALDH1A1KDM4EALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108102050-A | A kind of high-intensity water absorbent resin balls and preparation method thereof | 南京工业职业技术学院 | 2018-06-01 | — | — | CN | claimed |
| EP-4294800-B1 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260055083-A1 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4573077-A1 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| WO-2024249252-A1 | METHODS OF USING APOL1 INHIBITORS | MAZE THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20240316038-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2024-09-26 | — | — | US | disclosed |
| WO-2024040235-A1 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| EP-4294800-A1 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| US-11827637-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2023-11-28 | — | — | US | disclosed |
| CN-116997546-A | APOL1 inhibitors and methods of use | 梅兹治疗公司 | 2023-11-03 | — | — | CN | disclosed |
| US-20100292293-A1 | THERAPEUTIC SUBSTITUTED LACTAMS | OLD DAVID W | 2010-11-18 | — | — | US | disclosed |
| US-20100292293-A1 | THERAPEUTIC SUBSTITUTED LACTAMS | OLD DAVID W | 2010-11-18 | — | — | US | disclosed |
| US-7799775-B2 | such as 3-amino-5,6-dimethyl-2-[3-(4-quinolin-2-ylpiperazin-1-yl)propylthio]-3H-thieno[2,3-d]pyrimidin-4-one, having serotonin receptor modulatory activity, used for treating irritable bowel syndrome | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-09-21 | — | — | US | disclosed |
| EP-2215084-A2 | THERAPEUTIC SUBSTITUTED LACTAMS | ALLERGAN, INC. (US) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009055289-A2 | THERAPEUTIC SUBSTITUTED LACTAMS | ALLERGAN, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009055289-A2 | THERAPEUTIC SUBSTITUTED LACTAMS | ALLERGAN, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
| US-20070197551-A1 | Pyrimidine derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-23 | — | — | US | disclosed |
| EP-1724267-A1 | PYRIMIDINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2006-11-22 | — | — | EP | disclosed |
| US-5459142-A | Autoimmune disease, atherosclerosis, antiischemic agents and nephritis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-10-17 | — | — | US | disclosed |
| EP-0511879-A1 | Pyrazine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197551-A1 | Pyrimidine derivatives | HTR3B, HTR3A, HTR1A | TSHR 1069/4885IDO1 118/4885TDP1 2178/4885 |
| US-20100292293-A1 | THERAPEUTIC SUBSTITUTED LACTAMS | MRPL21, TUBB6, GOT1 | TSHR 4327/4885IDO1 2470/4885TDP1 3188/4885 |
| US-11827637-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | MAPKAPK2, MAPK1, MAPK7 | TSHR 2181/4885IDO1 917/4885TDP1 2442/4885 |
| US-20260055083-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, LDLR, APOB | TSHR 1084/4885IDO1 3095/4885TDP1 1024/4885 |
| US-20240316038-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, SAAL1, APOB | TSHR 2856/4885IDO1 2669/4885TDP1 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.